Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554695 · ClinicalTrials.gov registry record · Early Phase 1
Osteoclast Inhibition and Bone Formation
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 81
- Enrollment target
NCT02554695: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT02554695 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 81 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554695, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
Primary Outcome
Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm).
Interventions
- DRUG placebo
- DRUG denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-10-20 |
| Est. Completion | 2016-10-25 |
| Phase | Early Phase 1 |
What the finished NCT02554695 record still lists
NCT02554695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02554695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02554695 about?
NCT02554695 is a clinical study titled "Osteoclast Inhibition and Bone Formation". This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
What is the current status of trial NCT02554695?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 81 participants. The study started on 2015-10-20. Estimated completion is 2016-10-25.
What interventions are being tested in trial NCT02554695?
The interventions under investigation include: placebo (DRUG), denosumab (DRUG).
Who is sponsoring clinical trial NCT02554695?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02554695's enrollment target sits among peer trials
81 269th of 2000 higher than 1,730 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI